Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GC304
- Development stage
- Phase 1
- Lead developer
- GeneCradle
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
GC304 is a gene therapy drug developed by GeneCradle Inc. It is designed for the treatment of primary hypertriglyceridemia, specifically in patients who have a history of acute pancreatitis. The therapy involves the intravenous delivery of a self-complementary adeno-associated virus serotype 5 (AAV5) vector. This vector carries a codon-optimized lipoprotein lipase (LPL) coding sequence, which is driven by a liver-specific promoter (LP), aiming to restore or enhance LPL activity for improved triglyceride metabolism.
02
Targets
LPL (Lipoprotein lipase)
Beyond the preview
Go deeper on GC304.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GC304.